Stockscreener 앱 받기
25.61
3.31%
0.82
시간 외 거래:
25.61
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Barclays PLC - MarketBeat
Wellington Management Group LLP Lowers Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 52-Week LowHere's Why - MarketBeat
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - The Eastern Progress Online
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - The Eastern Progress Online
Ideaya Biosciences keeps stock target, Outperform on robust medicine pipeline - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Declines By 11.2% - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Outperform" Rating from Wedbush - MarketBeat
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Par - GuruFocus.com
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - Quantisnow
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - The Malaysian Reserve
IDEAYA nominates IDE251 for cancer treatment development By Investing.com - Investing.com South Africa
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PR Newswire
IDEAYA nominates IDE251 for cancer treatment development - Investing.com
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers – Company Announcement - Financial Times
IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years - Yahoo Finance
Indo-Asian News Service - IANS India Pvt Ltd
State Street Corp Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.67 Consensus Price Target from Analysts - MarketBeat
(IDYA) Proactive Strategies - Stock Traders Daily
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week LowShould You Sell? - MarketBeat
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 - Kilgore News Herald
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - The Eastern Progress Online
Ideaya Biosciences stock hits 52-week low at $25.16 - Investing.com India
Ideaya Biosciences stock hits 52-week low at $25.16 By Investing.com - Investing.com UK
IDEAYA Biosciences' SWOT analysis: precision oncology stock poised for growth - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
BNP Paribas Financial Markets Decreases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events - Victoria Advocate
IDEAYA begins trial of new cancer drug combo By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - The Eastern Progress Online
IDEAYA begins trial of new cancer drug combo - Investing.com India
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - Marketscreener.com
Ideaya nominates IDE-892 as development candidate - BioWorld Online
IDEAYA Biosciences Unveils IDE892, Breakthrough Cancer Drug Candidate with Promising Preclinical Results - StockTitan
2.88%
2.65%
자본화:
|
볼륨(24시간):